IFNGR1 and cancer: Moreover, mutations in the genes encoding interferon gamma receptor 1 (IFNGR1) or its signal transducer Janus kinase 2 (JAK2) have been associated with poor disease outcome in various cohorts of patients with cancer receiving immune checkpoint inhibitors (ICIs) [2].